Clinical trial
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal…
NCT00061594 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00061594 |
|---|---|
| Title | A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration |
| Official title | A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | rhuFab V2 (ranibizumab) |
| Enrollment | 426 |
| Start date | May 1, 2003 |
| Completion | Sep 1, 2006 |
| First posted | May 30, 2003 |
| Last update posted | Mar 19, 2014 |
| Countries | Australia, Czechia, France, Germany, Hungary, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: